129 related articles for article (PubMed ID: 36250599)
21. Psychosis and synthetic cannabinoids.
Deng H; Verrico CD; Kosten TR; Nielsen DA
Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871
[TBL] [Abstract][Full Text] [Related]
22. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis.
Mensen VT; Vreeker A; Nordgren J; Atkinson A; de la Torre R; Farré M; Ramaekers JG; Brunt TM
Psychopharmacology (Berl); 2019 Sep; 236(9):2677-2685. PubMed ID: 30968175
[TBL] [Abstract][Full Text] [Related]
23. Surveillance for Violent Deaths - National Violent Death Reporting System, 27 States, 2015.
Jack SPD; Petrosky E; Lyons BH; Blair JM; Ertl AM; Sheats KJ; Betz CJ
MMWR Surveill Summ; 2018 Sep; 67(11):1-32. PubMed ID: 30260938
[TBL] [Abstract][Full Text] [Related]
24. Review of the many faces of synthetic cannabinoid toxicities.
Alipour A; Patel PB; Shabbir Z; Gabrielson S
Ment Health Clin; 2019 Mar; 9(2):93-99. PubMed ID: 30842917
[TBL] [Abstract][Full Text] [Related]
25. The effects of synthetic cannabinoids (SCs) on brain structure and function.
Livny A; Cohen K; Tik N; Tsarfaty G; Rosca P; Weinstein A
Eur Neuropsychopharmacol; 2018 Sep; 28(9):1047-1057. PubMed ID: 30082140
[TBL] [Abstract][Full Text] [Related]
26. Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015).
Kasper AM; Ridpath AD; Gerona RR; Cox R; Galli R; Kyle PB; Parker C; Arnold JK; Chatham-Stephens K; Morrison MA; Olayinka O; Preacely N; Kieszak SM; Martin C; Schier JG; Wolkin A; Byers P; Dobbs T
Clin Toxicol (Phila); 2019 Jan; 57(1):10-18. PubMed ID: 29989463
[TBL] [Abstract][Full Text] [Related]
27. Suicide Trends Among and Within Urbanization Levels by Sex, Race/Ethnicity, Age Group, and Mechanism of Death - United States, 2001-2015.
Ivey-Stephenson AZ; Crosby AE; Jack SPD; Haileyesus T; Kresnow-Sedacca MJ
MMWR Surveill Summ; 2017 Oct; 66(18):1-16. PubMed ID: 28981481
[TBL] [Abstract][Full Text] [Related]
28. Cannabis and synthetic cannabinoid poison control center cases among adults aged 50+, 2009-2019.
Choi NG; Marti CN; DiNitto DM; Baker SD
Clin Toxicol (Phila); 2021 Apr; 59(4):334-342. PubMed ID: 32840426
[TBL] [Abstract][Full Text] [Related]
29. Regional Differences in Mortality Rates and Characteristics of Decedents With Hepatitis B Listed as a Cause of Death, United States, 2000-2019.
Ly KN; Yin S; Spradling PR
JAMA Netw Open; 2022 Jun; 5(6):e2219170. PubMed ID: 35763293
[TBL] [Abstract][Full Text] [Related]
30. Causal inference multiple imputation investigation of the impact of cannabinoids and other substances on ethnic differentials in US testicular cancer incidence.
Reece AS; Hulse GK
BMC Pharmacol Toxicol; 2021 Jul; 22(1):40. PubMed ID: 34246312
[TBL] [Abstract][Full Text] [Related]
31. Synthetic cannabinoids: the dangers of spicing it up.
Salani DA; Zdanowicz MM
J Psychosoc Nurs Ment Health Serv; 2015 May; 53(5):36-43. PubMed ID: 25974923
[TBL] [Abstract][Full Text] [Related]
32. Uses, Effects and Toxicity of Synthetic Cannabinoids from the Perspective of People with Lived Experiences.
Assi S; Marshall D; Bersani FS; Corazza O
J Psychoactive Drugs; 2020; 52(3):237-247. PubMed ID: 32027228
[TBL] [Abstract][Full Text] [Related]
33. Critical Illness Secondary to Synthetic Cannabinoid Ingestion.
Kourouni I; Mourad B; Khouli H; Shapiro JM; Mathew JP
JAMA Netw Open; 2020 Jul; 3(7):e208516. PubMed ID: 32687586
[TBL] [Abstract][Full Text] [Related]
34. International trends in spice use: Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids.
Loeffler G; Delaney E; Hann M
Brain Res Bull; 2016 Sep; 126(Pt 1):8-28. PubMed ID: 27108542
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study.
Shalit N; Barzilay R; Shoval G; Shlosberg D; Mor N; Zweigenhaft N; Weizman A; Krivoy A
J Clin Psychiatry; 2016 Aug; 77(8):e989-95. PubMed ID: 27379411
[TBL] [Abstract][Full Text] [Related]
36. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
[No Abstract] [Full Text] [Related]
37. Brief report: Synthetic cannabinoid use among military personnel.
Stogner J; Santangelo O; Baldwin JM
Am J Addict; 2024 Jan; 33(1):96-99. PubMed ID: 37717217
[TBL] [Abstract][Full Text] [Related]
38. Changes in the Demographic Distribution of Chicago Gun-Homicide Decedents From 2015-2021: Violent Death Surveillance Cross-sectional Study.
Mason M; Khazanchi R; Brewer A; Sheehan K; Liu Y; Post L
JMIR Public Health Surveill; 2023 Apr; 9():e43723. PubMed ID: 37027193
[TBL] [Abstract][Full Text] [Related]
39. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
Castaneto MS; Gorelick DA; Desrosiers NA; Hartman RL; Pirard S; Huestis MA
Drug Alcohol Depend; 2014 Nov; 144():12-41. PubMed ID: 25220897
[TBL] [Abstract][Full Text] [Related]
40. Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services.
Monti MC; Zeugin J; Koch K; Milenkovic N; Scheurer E; Mercer-Chalmers-Bender K
Drug Test Anal; 2022 Jun; 14(6):1026-1039. PubMed ID: 34997693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
